Journal Club

What is it?

The purpose of the CSHP OB Journal Club is to foster evidence-based, timely and contextualized learning that has immediate or near-future implications on front-line practice. Journal Club is structured as a 30-minute facilitated discussion over teleconference occurring on the last Thursday of each month (except December and January) from 1200-1230h. 

Papers are disseminated by email 2-3 weeks in advance with accompanying backgrounder articles to enhance understanding of the topic where appropriate. Participation is open to all CSHP members and is completely voluntary. Some pharmacists may prefer to read the articles on their own, while others may call in more or less regularly if they prefer to have a discussion or learn how other hospitals and pharmacists are approaching a particular clinical problem. The overall atmosphere is informal and conversational as we learn clinical pearls from each other and share common wins and challenges in our own practices. 

Papers are not limited to randomized controlled trials. Systematic reviews, narrative reviews, meta-analyses, cohort/case control studies, clinical guidelines, teachable moments, commentaries on clinical practice, ISMP Canada Safety Bulletins, CJHP point/counterpoint articles and Health Canada's Health Product InfoWatch publications will also be chosen based on their applicability to clinical practice. CSHP members are always encouraged to suggest topics and/or articles for future journal club sessions.

Upcoming Journal Club:​​​​

Topic: Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants

Article: 2019 Annals of Oncology 30:897-907 - https://academic.oup.com/annonc/article/30/6/897/5421158

Date: Wednesday, October 30th, 2019
Time: 12-12:30 PM EST

Contact for registration and information:

Maria Marchese, RPh ACPR PharmD
Clinical Pharmacist
Thunder Bay Regional Health Sciences Centre
Northwestern Chapter

maria.marchese@mail.utoronto.ca

Actual comment: “ I have a patient with a history of cancer and associated VTE admitted with mild AKI due to a urologic procedure complication. He was on rivaroxaban at home..is there a problem here? ” During this session, we will review the evidence for treating VTE in cancer patients with direct oral anticoagulants using the article above. We will compare clinical practice guideline recommendations to landmark trial findings and discuss how this relates within current practice issues.

Please RSVP to maria.marchese@mail.utoronto.ca by October 29th to confirm your attendance.
Once you submit your RSVP you will be provided with the details regarding the teleconference code /web sign in access.

 

2019 Journal Clubs

September 2019

Primary article: Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics
Backgrounder article: Should prolonged infusion of ß-lactams become standard of practice?

August 2019

A Painful Medication Reconciliation Mishap
Diagnosis and Pharmacotherapy of Alcohol-Use Disorder: A Review

May 2019

SLGT2 inhibitors – Are they the new class in heart failure?

April 2019

American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults – A Review of the Updates and Deprescribing

February 2019

Emerging cases in the ER: Managing Cannabinoid Hyperemesis Syndrome (CHS)

January 2019
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthoplasty (EPCAT2)

 

2018 Journal Clubs

February 2018

Can DOACs be used to treat cancer-associated VTEs? A look at edoxaban.

March 2018

Understanding the why and how of obesity dosing for antibiotics: a narrative review of literature from 1966 to 2017

April 2018

Deprescribing opportunities in acute care – guidance from Choosing Wisely Canada. Part 1: Stool softeners, PPIs, benzodiazepines/sedative-hypnotics and combination ACEI/ARB therapy

May 2018

Deprescribing opportunities in acute care – guidance from Choosing Wisely Canada. Part 2: Statins, opioids, antipsychotics and antibiotics for asymptomatic bacteriuria.

June 2018

Improving the pharmacist handover process in the hospital: the I-HAPPY tool

July 2018

The revolving door of COPD exacerbations – how can we better optimize therapy before discharging the patient?

August 2018

Diluent shortages in the wake of Hurricane Maria: What can they teach us about the way we practice medicine?

September 2018

Are we ready for our next overdose patient? A discussion of recommended antidotes to be stocked in hospitals and national initiatives under development.

October 2018

Marijuana legalization on October 17: Reviewing medical marijuana therapy in acute care and considerations for unique inpatient populations.

November 2018

Who is at risk of oversedation in the hospital? Taking a closer look at the FROSH factors.

2017 Journal Clubs

November 2017

Point counterpoint: Should digoxin continue to be used for atrial fibrillation?

October 2017

Managing diabetic emergencies – ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS) and hypoglycemia. Are we using evidence-based approaches?

September 2017

Medical marijuana – what is the evidence?
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

August 2017

Idarucizumab for dabigatran reversal(REVERSE-AD trial) Part 2 – Full cohort analysis

July 2017

Tackling one piece of the opioid crisis: Opioid initiation in the ER
Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use.

June 2017

Can PPI and H2 blocker stewardship reduce the risk of clostridium difficile infections?
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.
Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults.

May 2017

Are we underdosing VTE prophylaxis in our obese patients?
Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.

April 2017

Teachable moments:
1) How to clarify a penicillin allergy
2) how to help patients sleep better in the hospital

March 2017

Incretin-based antihyperglycemics and acute pancreatitis: is there a link?
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

February 2017

Med Safety Blast – Health Product InfoWatch November and December 2016 issues

January 2017

Use of potentially inappropriate medications in alternate level of care (ALC) inpatients and a practical review of Beers Criteria
Application of the Beers Criteria to Alternate Level of Care Patients in Hospital Inpatient Units

2016 Journal Clubs

November 2016

Using DOACs in morbid obesity – should we be worried?
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
NOACS/DOACS: Coagulation Tests

October 2016

Triple antithrombotic therapy – are we doing it right?
Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention.

September 2016

Improving inhaler technique for hospitalized patients with COPD
Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease.

August 2016

Opioid discussions Part 2: Naloxone kits and Ontario Drug Benefit’s delisting of certain long-acting opioids
Dispensing or Selling Naloxone: Guidance
Reminder regarding Delisting of High-Strength Long-Acting Opiods under the ODB Program

July 2016

Opioid discussions Part 1: Preventing opioid overdoses in acute care
Retrospective analysis of opioid medication incidents requiring administration of naloxone.

June 2016

Idarucizumab for dabigatran reversal (REVERSE-AD trial) Part 1: Preliminary results

May 2016

Considerations for intravenous to oral antibiotic stepdown
Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

April 2016

Crediblemeds.org and assessing QT prolonging risk of drugs in context of clinical scenarios
Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.

March 2016

Subsequent entry biologics and implications on the hospital formulary
New Advances in Immunology: SEBs in Rheumatology, Dermatology, and Gastroenterology

Febraury 2016

Toujeo vs. Lantus in glycemic control and weight gain
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.